Wednesday, November 11, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 15, 2026

Earnings live: Goldman Sachs and BlackRock profits beat, TSMC stock jumps on robust outlook

View original at finance.yahoo.com
Earnings live: Goldman Sachs and BlackRock profits beat, TSMC stock jumps on robust outlook The fourth quarter earnings season kicked off in earnest on Tuesday with the arrival of quarterly reports from Delta Air Lines (DAL) and JPMorgan Chase (JPM)…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • With less fear priced in, it is more difficult to see relief rallies on earnings days

    80% confidence
  • We're all in for affordability

    80% confidence
  • Investment banking segment could rebound in coming quarters as deals get pushed out

    80% confidence
  • Investors are expecting a low-volatility earnings season based on softer option volumes and balanced positioning

    80% confidence
  • On Sept. 30, the consensus estimate for S&P 500 fourth quarter earnings growth stood at 7.2%

    80% confidence
  • Wall Street analysts estimate S&P 500 companies will report an earnings per share growth rate of 8.3% for Q4

    80% confidence
  • Recent news flow has reminded investors that policy changes can sometimes be risks as well

    80% confidence
  • One big issue with the potential order is that it would restrict lower-end consumers from having access to any credit, which would upend the whole credit card industry

    80% confidence
  • An interest rate cap is not something that Citigroup would or could support

    80% confidence
  • If credit card rate cap happened as described, it would be dramatic

    80% confidence
  • Affordability is clearly an important issue and one that Citigroup looks forward to collaborating with the administration on

    80% confidence
  • Credit card rate cap would be a severely negative consequence for consumers and probably also for the economy as a whole

    80% confidence
  • Investors have grown to view policy as a one-way dynamic towards deregulation and factors beneficial to banks

    80% confidence
  • If 8.3% EPS growth rate holds, it would represent the 10th consecutive quarter of annual earnings growth for the S&P 500 index

    80% confidence
  • Interest rate cap would likely result in a significant slowdown in the economy

    80% confidence
  • TSMC expects 2026 revenue to increase by close to 30% year over year as artificial intelligence supports strong demand

    80% confidence
  • The only negative point in big bank results was really investment banking

    80% confidence
  • Utility, healthcare, materials, and industrial stocks have been making the most unusually large moves on earnings-day in recent quarters

    80% confidence
  • People will lose access to credit on a very extensive and broad basis, especially people who need it most, as a result of credit card rate cap

    80% confidence
  • There could be unintended consequences of credit card rate cap

    80% confidence
  • The average implied earnings day stock move is 4.5% in either direction, below the long-term average

    80% confidence
  • Don't see any way to even begin to contemplate how credit card rate cap would be implemented

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com
Earnings live: Goldman Sachs and BlackRock profits beat, TSMC stock jumps on robust outlook — Source | Via News | Via News